** Shares of telehealth platform Mangoceuticals MGRX.O rise 43% to 51 cents premarket

** Co says its new $99/month injectable testosterone therapy plan saw sales jump 336% month‑over‑month since mid‑December

** MGRX says it also cut its customer acquisition costs by more than half

** Mangoceuticals expects testosterone therapy to become its main growth driver

** In 2025, MGRX plunged 70%

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))